Market closedNon-fractional

4D Molecular Therapeutics/FDMT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About 4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Ticker

FDMT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

EmeryVille, United States

Employees

171

FDMT Metrics

BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$2.42
EPS
2.93
Beta
-
Dividend rate
$1.4B
2.93
32.652
32.062
1.831
2.36
-17.29%
-25.53%
57.583
2.31
2.31
-14.825
826.31%
-28.55%
19.20%
-21.92%

What the Analysts think about FDMT

Analyst Ratings

Majority rating from 10 analysts.
Buy

FDMT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$32M
-67.86%
Profit margin
0.00%
-100.00%

FDMT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.41%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.77
-$0.24
-$0.75
-$0.66
-
Expected
-$0.81
-$0.59
-$0.74
-$0.74
-$0.71
Surprise
-4.70%
-59.58%
1.18%
-10.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for 4D Molecular Therapeutics stock?

4D Molecular Therapeutics (FDMT) has a market cap of $1.4B as of July 15, 2024.

What is the P/E ratio for 4D Molecular Therapeutics stock?

The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of July 15, 2024.

Does 4D Molecular Therapeutics stock pay dividends?

No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of July 15, 2024.

When is the next 4D Molecular Therapeutics dividend payment date?

4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.

What is the beta indicator for 4D Molecular Therapeutics?

4D Molecular Therapeutics (FDMT) has a beta rating of 2.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell 4D Molecular Therapeutics stock

Buy or sell 4D Molecular Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing